QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.071282v1 311/2/537    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sullivan, S. K. Articles by Grigoriadis, D. E. Search for Related Content PubMed PubMed Citation Articles by Sullivan, S. K. Articles by Grigoriadis, D. E.

NEUROPHARMACOLOGY

Characterization of the Interaction of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic, with the GABA_A Receptor

Departments of Pharmacology (S.K.S., D.E.G.), Neuroscience (R.E.P., G.V., A.C.F.), and Medicinal Chemistry (R.S.G.), Neurocrine Biosciences Inc., San Diego, California

Clinically used benzodiazepine and nonbenzodiazepine sedative-hypnotic agents for the treatment of insomnia produce their therapeutic effects through allosteric enhancement of the effects of the inhibitory neurotransmitter GABA at the GABA_A receptor. Indiplon is a novel pyrazolopyrimidine sedative-hypnotic agent, currently in development for insomnia. Using radioligand binding studies, indiplon inhibited the binding of [³H]Ro 15-1788 (flumazenil) to rat cerebellar and cerebral cortex membranes with high affinity (K_i values of 0.55 and 0.45 nM, respectively). [³H]Indiplon binding to rat cerebellar and cerebral cortex membranes was reversible and of high affinity, with K_D values of 1.01 and 0.45 nM, respectively, with a pharmacological specificity consistent with preferential labeling of GABA_A receptors containing 1 subunits. In "GABA shift" experiments and in measurements of GABA-induced chloride conductance in rat cortical neurons in culture, indiplon behaved as an efficacious potentiator of GABA_A receptor function. In both the radioligand binding and electrophysiological experiments, indiplon had a higher affinity than zolpidem or zaleplon. These in vitro properties are consistent with the in vivo properties of indiplon as an effective sedative-hypnotic acting through allosteric potentiation of the GABA_A receptor.

Address correspondence to: Dr. Dimitri E. Grigoriadis, 12790 El Camino Real, San Diego, CA 92130. E-mail: dgrigoriadis{at}neurocrine.com

This article has been cited by other articles:

				J. C Marrs Indiplon: A Nonbenzodiazepine Sedative-Hypnotic for the Treatment of Insomnia Ann. Pharmacother., July 1, 2008; 42(7): 1070 - 1079. [Abstract] [Full Text] [PDF]

				S. Passarella and M.-T. Duong Diagnosis and treatment of insomnia Am. J. Health Syst. Pharm., May 15, 2008; 65(10): 927 - 934. [Abstract] [Full Text] [PDF]

				L. P. Carter, R. R. Griffiths, P. E. Suess, J. H. Casada, C. L. Wallace, and J. D. Roache Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 749 - 759. [Abstract] [Full Text] [PDF]

				R. E. Petroski, J. E. Pomeroy, R. Das, H. Bowman, W. Yang, A. P. Chen, and A. C. Foster Indiplon Is a High-Affinity Positive Allosteric Modulator with Selectivity for {alpha}1 Subunit-Containing GABAA Receptors J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 369 - 377. [Abstract] [Full Text] [PDF]

				A. C. Foster, M. A. Pelleymounter, M. J. Cullen, D. Lewis, M. Joppa, T. K. Chen, H. P. Bozigian, R. S. Gross, and K. R. Gogas In Vivo Pharmacological Characterization of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 547 - 559. [Abstract] [Full Text] [PDF]